title: Bispecific antibodies and their applications.
abstract: Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up a wide range of applications, including redirecting T cells to tumor cells, blocking two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to targeted sites. The approval of catumaxomab (anti-EpCAM and anti-CD3) and blinatumomab (anti-CD19 and anti-CD3) has become a major milestone in the development of bsAbs. Currently, more than 60 different bsAb formats exist, some of them making their way into the clinical pipeline. This review summarizes diverse formats of bsAbs and their clinical applications and sheds light on strategies to optimize the design of bsAbs.
authors.affiliation: National Center for Clinical Laboratories, Beijing Hospital, No 1 Dahua Road, Dongdan, Beijing, 100730, China. gaoweifan163@163.com.|Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China. gaoweifan163@163.com.
authors.forename: Gaowei
authors.initials: G
authors.lastname: Fan
authors.affiliation: Shunyi District Maternal and Child Health Hospital of Beijing City, Beijing, 101300, China. wangzujian0714@163.com.
authors.forename: Zujian
authors.initials: Z
authors.lastname: Wang
authors.affiliation: National Center for Clinical Laboratories, Beijing Hospital, No 1 Dahua Road, Dongdan, Beijing, 100730, China. haomingju@163.com.|Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China. haomingju@163.com.
authors.forename: Mingju
authors.initials: M
authors.lastname: Hao
authors.affiliation: National Center for Clinical Laboratories, Beijing Hospital, No 1 Dahua Road, Dongdan, Beijing, 100730, China. jmli@nccl.org.cn.|Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China. jmli@nccl.org.cn.
authors.forename: Jinming
authors.initials: J
authors.lastname: Li
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D009369:Neoplasms / Q000098:blood supply / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; C510808:blinatumomab; C522419:catumaxomab